Dice Therapeutics initiated with a Buy at Needham 03/31 DICE Needham initiated coverage of Dice Therapeutics with a Buy rating and $56 price target. Dice is a clinical-stage biotech developing oral therapeutics against "well-validated" immunology targets with the goal of delivering comparable efficacy to commercially established biologics for various immune-related diseases, the analyst tells investors in a research note. The firm believes Dice offers a "rare pure-play opportunity" to invest in an area of significant takeover interest for large pharma. Show Related Items >> Dice Therapeutics discloses $14.8M purchase of common stock by Ra Capital 03/30 DICE In a regulatory filing, Dice Therapeutics disclosed that Ra Capital bought 509K shares of common stock on March 28th in a total transaction size of $14.8M. Shares of Dice Therapeutics are up 2% afterhours at $29.24.
Company Profile PureCycle Technologies, Inc. produces recycled polypropylene (PP). The company holds a license for restoring waste PP into ultra-pure recycled resin. Its recycling process separates color, odor, and other contaminants from plastic waste feedstock to transform it into virgin-like resin. PureCycle Technologies, Inc. was founded in 2015 and is headquartered in Orlando, Florida.